Sera and biopsied liver specimens from 45 hepatitis B surface antigen (HBsAg) carriers both with or without overt liver diseases and negative for anti-delta antibody, were examined for markers of hepatitis B virus (HBV) infection: hepatitis B e antigen (HBeAg), hepatitis B virus deoxyribonucleic acid (HBV-DNA) in serum and hepatitis B core antigen (HBcAg) in liver. HBV-DNAin serum was assayed by the spot hybridization technique, and HBcAg in the liver was investigated by the peroxidase anti-peroxidase m ethod. Among the parameters showing active replication of HBV, serum HBeAg , serum HBV-DNA and intrahepatic HBcAg were found in 27 (60%), 27 (60%) and in 22 (48.9%) of 45 HBsAg carriers, respectively. The presence of serum HBV-DNAand of intrahepatic HBcAg in HBeAg positive cases and the absence of serum HBV-DNAand of intrahepatic HBcAg in anti-HBe positive cases was the rule with few disparate cases amongthose with chronic liver disease. These parameters were not useful in predicting the histology on liver biopsy. The activity of hepatic inflammation in the HBsAg chronic carriers assessed by serum alanine aminotransferase level closely paralleled HBV-DNAin serum but not HBeAg in serum, HBcAg in liver or histologic picture on biopsy. HBV-DNAmay be the most sensitive parameter of replication of hepatitis B virus and of the activity of inflammation in the liver.
The presence of hepatitis B e antigen (HBeAg) in the serum of hepatitis B surface antigen (HBsAg) carriers has generally been considered a reflection of active replication of hepatitis B virus (HBV) and high infectivity, whereas the presence of antibody to hepatitis B e antigen (anti-HBe) in serum has been regarded as an indication of regression of liver disease activity and a low grade of infectivity1' 2' 3^. More recently, however, it has been shown that a substantial number of anti-HBe positive patients have demonstrable hepatitis B core antigen in liver which signifies active HBV replication4' 5-*. Furthermore, recent reports have described patients positive for anti-HBe with active HBV replication shown by hepatitis B virus DNA (HBV-DNA) in serum5 '6'7'8'9 Serum samples and liver-biopsied specimens from 45 Japanese patients referred to Shinshu University Hospital because they had been HBsAg positive for more than 6 months. There were 38 men and 7 women, ranging in age from 18 to 54. Of 45 HBsAg carriers, 14 were identified at the time blood donation, 10 were found to have HBsAg on family health screening because of liver disease in other family members, 9 were found to have HBsAg on routine health screening, and 12 visited physicians due to nonspecific complaints such as fatigue, anorexia, nausea, and vomiting and were found on laboratory studies to be HBsAg positive.
All were referred to the University for investigation of the activity of liver disease and infectivity for hepatitis B virus (HBV). None had a history of blood transfusion or illicit self injection. None had received antiviral or immunosuppressive drugs during the 6 months prior to our examination and follow-up. All patients were followed for one year or more after liver biopsy.
Each patient liver was biopsied under peritoneoscopy and processed for routine histological staining after fixation in 10% formaline and embedding in paraffine. All serum samples used in this study were taken on the same day that the liver biopsy was performed. with 32P by nick translation at a specific activity of 2 -4 x 10 dpm/ug. Each sample (150 microliters) was denatured in 150 microliters of 2M NaCl and 300 microliters of 1M NaOH at room temperature for 10 minutes; the mixture was spotted on a nylon membrane (Biodyne A, Pall Corp., Glen Cove, N.Y.) under a negative pressure through a filter apparatus. After the filter was drained, 600 microliters of 0.5M Tris-HCl, 3M NaCl (pH7.4) was passed through it; the membrane was then removed and baked in a vacuum at 80 C for 2 hours. The membrane was incubated at 42°C over night with a prehybridization solution containing 50% (vol/vol) formamide, 6 x SSC (0.9M NaCl, 0.09M sodium citrate), 5 x 
